Preparation and in vitro-in vivo evaluation of QbD based acemetacin loaded transdermal patch formulations for rheumatic diseases

Basit Öğe Kaydı
dc.authoridEce Özcan Bülbül / 0000-0001-7112-923Xen_US
dc.authorscopusidEce Özcan Bülbül / 57211920637en_US
dc.authorwosidEce Özcan Bülbül / GLX-5211-2022en_US
dc.contributor.authorBülbül, Ece Özcan
dc.contributor.authorHüssein, Hasan Ali
dc.contributor.authorYegen, Gizem
dc.contributor.authorOkur, Mehmet Evren
dc.contributor.authorÜstünda, Neslihan
dc.contributor.authorAksu, Neşe Buket
dc.date.accessioned2023-08-31T12:13:39Z
dc.date.available2023-08-31T12:13:39Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümüen_US
dc.description.abstractThis research aimed to develop patches for transdermal delivery of acemetacin, which can be used to treat rheumatic diseasesand to determine their potential use. Patches were successfully created by solvent casting method using hydroxypropyl methylcellulose, propylene glycol, polyethylene glycol 400, tween 80, and dimethyl sulfoxide. Prepared patches were found using the Design of Experiments (DoE) method within the Quality by Design (QbD) approach. F1-ACM with a thickness of 0.1 +/- 0.0 cm, a weight of 43.33 +/- 6.29 mg, pH of 4.99 +/- 0.24, moisture content of 18.33 +/- 2.98%, a tensile strength of 9.196 +/- 0.441 Mpa, elongation at break of 28.722 +/- 0.803% and drug content of 100% was chosen as ideal formulation. 89.7% of ACM from F1-ACM was released in 5 min. F1-ACM significantly (p < 0.05) increased the response latency to the thermal stimulus at 90th (3.071 +/- 0.517) and 120th (3.87 +/- 0.332) min in the hot plate test. In the tail-flick experiment, F1-ACM significantly (p < 0.05) increased the reaction delay against heat stimuli at 90th (3.016 +/- 0.695), 120th (2.884 +/- 0.851), and 180th (2.893 +/- 0.932) min. F1-ACM patch significantly (p < 0.001) inhibited paw edema formation at 1, 2, 3, 4, and 5 h after induction of inflammation as compared to the control group. Therefore, this formulation can be employed more efficiently for rheumatic disease.en_US
dc.identifier.citationÖzcan Bülbül, E., Husseın, H. A., Yeğen, G., Okur, M. E., Üstündağ Okur, N., & Aksu, N. B. (2022). Preparation and in vitro–in vivo evaluation of QbD based acemetacin loaded transdermal patch formulations for rheumatic diseases. Pharmaceutical Development and Technology, 1-11.en_US
dc.identifier.doi10.1080/10837450.2022.2145308en_US
dc.identifier.pmid36583670en_US
dc.identifier.scopus2-s2.0-85145394520en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttp://dx.doi.org/10.1080/10837450.2022.2145308
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3966
dc.identifier.wosWOS:000905221400001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorBülbül, Ece Özcan
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofPharmaceutical Development and Technologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcemetacinen_US
dc.subjectPatchen_US
dc.subjectQbDen_US
dc.subjectTransdermalen_US
dc.subjectAnalgesic Activityen_US
dc.subjectAnti-Inflammatory Drugen_US
dc.titlePreparation and in vitro-in vivo evaluation of QbD based acemetacin loaded transdermal patch formulations for rheumatic diseasesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Ozcan-bulbul-2022-Preparation-and-in-vitroin-vivo-eva.pdf
Boyut:
2.28 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu